Biohaven (BHVN) Total Debt (2025 - 2026)

Biohaven (BHVN) reported Total Debt of $241.9 million for Q1 2026, up 1.26% sequentially from $238.9 million in Q4 2025.

Biohaven (BHVN) Total Debt (2025 - 2026) Analysis & Trends

Biohaven (BHVN) has 2 years of Total Debt data on file, last reported at $241.9 million in Q1 2026.

For the quarter ending Q1 2026, Total Debt changed N/A year-over-year to $241.9 million; the trailing twelve-month figure through Mar 2026 stood at $241.9 million (changed N/A YoY), and the FY2025 full-year result was $238.9 million, changed N/A from the prior year.
Total Debt grew to $241.9 million in Q1 2026, from $238.9 million in the prior quarter.
In the past five years, Total Debt ranged from a high of $268.3 million in Q3 2025 to a low of $238.9 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	110.96 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	959.06 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	1.99 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Biohaven	2.16 Bn	1.81 Bn	-	241.91 Mn

Download Data